Protalix BioTherapeutics (PLX) Free Cash Flow Growth (1y) (2011 - 2026)
Protalix BioTherapeutics (PLX) Free Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,921.77 Bn | 66,921.49 Bn | - | 7.12% |
| 2 | Nanobiotix | 1,924.26 Bn | 1,924.20 Bn | - | - |
| 3 | Akari Therapeutics | 975.59 Bn | 975.59 Bn | - | - |
| 4 | BeOne Medicines | 471.47 Bn | 466.67 Bn | 1.35 Bn | 1,092.51% |
| 5 | Vertex Pharmaceuticals | 121.76 Bn | 114.52 Bn | 2.59 Bn | 66.37% |
| 6 | Regeneron Pharmaceuticals | 69.90 Bn | 61.15 Bn | 3.31 Bn | 3.98% |
| 7 | Belite Bio | 62.83 Bn | 62.83 Bn | - | - |
| 8 | Argenx Se | 55.77 Bn | 50.59 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.45 Bn | 37.45 Bn | - | - |
| 10 | Protalix BioTherapeutics | 192.04 Mn | 181.24 Mn | 29.62 Mn | 487.68% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 487.68% |
| Dec 31, 2025 | -18.79% |
| Sep 30, 2025 | -236.21% |
| Jun 30, 2025 | -44.60% |
| Mar 31, 2025 | -235.70% |
| Dec 31, 2024 | -8.09% |
| Sep 30, 2024 | 145.93% |
| Jun 30, 2024 | -173.96% |
| Mar 31, 2024 | 221.60% |
| Dec 31, 2023 | 252.22% |
| Sep 30, 2023 | 21.37% |
| Jun 30, 2023 | 165.77% |
| Mar 31, 2023 | 43.62% |
| Dec 31, 2022 | 38.87% |
| Sep 30, 2022 | -319.42% |
| Jun 30, 2022 | -218.20% |
| Mar 31, 2022 | 42.31% |
| Dec 31, 2021 | 44.30% |
| Sep 30, 2021 | 39.99% |
| Jun 30, 2021 | 177.48% |